Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 421-427

  Culine, Stéphane ^a   Kramar, Andrew ^a   Théodore, Christine ^a   Geoffrois, Lionel ^a   Chevreau, Christine ^a   Biron, Pierre ^a   Nguyen, Binh Bui ^a   Héron, Jean François ^a   Kerbrat, Pierre ^a   Caty, Armelle ^a   Delva, Rémy ^a   Fargeot, Pierre ^a   Fizazi, Karim ^a   Bouzy, Jeannine ^a   Droz, Jean Pierre ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HORMONE BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; HUMANS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RETROPERITONEAL NEOPLASMS; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; VINBLASTINE;

EID: 38649104783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.8461     Document Type: Article

References (23)

1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
2. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
3. Schmoll HJ, Souchon R, Krege S, et al: European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15:1377-1399, 2004
4. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
5. Williams SD, Birch R, Einhorn L, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
6. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
7. Nichols CR, Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol 16:1287-1293, 1998
8. de Wit R, Stoter G, Sleijfer DTh, et al: Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular nonseminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 78:828-832, 1998
9. Hinton S, Catalano PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an Intergroup trial. Cancer 97:1869-1875, 2003
10. Droz JP, Kramar A, Biron P, et al: Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: Mature results of a randomised trial. Eur Urol 51:739-748, 2007
11. Motzer RJ, Nichols CR, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247-256, 2007
12. Samuels ML, Holoye PY, Johnson DE: Bleomycin combination chemotherapy for metastatic testicular carcinoma. Cancer Bull 25:53-55, 1973
13. Logothetis CJ, Trindade A, Samuels ML: Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 3:326-335, 1985
14. Logothetis CJ, Samuels ML, Selig D, et al: Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors: Results with 100 patients. Am J Med 81:219-228, 1986
15. IV) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. Am J Clin Oncol 20:184-188, 1997
16. Fizazi K, Do KA, Wang X, et al: A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ cell tumors: Final results of a phase III randomized trial. Ann Oncol 13:125-134, 2002
17. Droz JP, Kramar A, Ghosn M, et al: Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer 62:564-568, 1988
18. Miller AB, Hoogstraten B, Staquet B, Winkler A: Reporting results of cancer treatment. Cancer 47:207-214, 1981
19. Droz JP, Pico JL, Ghosn M, et al: A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. Bull Cancer 79:497-507, 1992
20. de Wit R, Stoter G, Sleijfer DT, et al: Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71:1311-1314, 1995
21. Kaye SB, Mead GM, Fossa SD, et al: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poorprognosis metastatic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 16:692-701, 1998
22. Samson MK, Rivkin SE, Jones SE, et al: Dose-response and dose-survival advantage for high versus low dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. Cancer 53:1029-1035, 1984
23. Fizazi K, Culine S, Kramar A, et al: Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22:3868-3876, 2004